BLACK WEEKSBočice −15% · kompleti −10% · ostalo −5%s kodomBesplatna dostava u Njemačkoj od 200 €

Ova je stranica automatski prevedena i može sadržavati pogreške. Jeste li izvorni govornik? Rado ćemo primiti vaše povratne informacije i ispravke.Pošaljite povratne informacije

The Peptide Desk The Peptide Desk
Insulin Glargin (Lantus), fotografija proizvoda
Medication

Insulin Glargin (Lantus)

Medication

  • Šalje se iz Njemačke

Narudžba

Jedinična cijena - Besplatna dostava u Njemačkoj iznad 200 € tijekom akcije Black Weeks
  • DHL s praćenjem
  • Diskretno pakiranje

4.6 od 5 na Trustpilotu73 recenzija

Na prvi pogled

Insulin Glargin (Lantus) u brojkama

Ključni podaci iz našeg leksikona.

Cijeli članak u leksikonu
Class
Long-acting insulin analoguebasal insulin
Use
Subcutaneous1x daily at a fixed time of day
Sizes
3ml/300iu1 size in the shop

Za Insulin Glargin (Lantus) još nema laboratorijske analize. Glasaj za toSve laboratorijske analize

Znanje

Sve o Insulin Glargin (Lantus)

FAQ

Česta pitanja

Izvori za svaki odgovor: članak u leksikonu

Imate još pitanja?

Pišite nam, naš tim će vam pomoći.

Why does Insulin Glargine act so long?

Under the skin glargine forms a fine depot and dissolves slowly. In a 24-hour clamp the effect began after about 1.5 hours, there was no peak and it ended after about 22 hours. NPH insulin peaked at 4.5 hours and ended after 14 hours.

Is Insulin Glargine approved?

Yes. ChEMBL lists Insulin Glargine as an approved drug with first approval in 2000. On ClinicalTrials.gov more than 700 trials list Insulin Glargine among their interventions (as of 25 October 2026). Everything here is the state of research, not a recommendation.

Is there less hypoglycaemia than with NPH insulin?

In two large comparisons yes. In 534 adults with type 1 diabetes 18.2 instead of 27.1 percent had night-time hypoglycaemia. In 756 people with type 2 diabetes 33.2 instead of 26.7 percent reached the target without night-time hypoglycaemia while the long-term value was practically the same with both insulins.

What did the ORIGIN trial show?

12,537 people with cardiovascular risk and impaired glucose metabolism received glargine or standard care for a median of 6.2 years. Cardiovascular events and cancer did not differ. Severe hypoglycaemia was more than three times as common at 1.00 versus 0.31 per 100 person-years and weight rose by a median of 1.6 kg instead of falling by 0.5 kg.

Does glargine act the same every day?

Not quite. Under clamp conditions the effect varied less from day to day with glargine than with NPH insulin but more than with insulin detemir (coefficient of variation over 24 hours 48 versus 68 and 27 percent). A flat average profile does not rule out deviations in individual cases.

What is the biggest risk?

Hypoglycaemia over a long action window. A depot under the skin cannot be retrieved, too high a dose keeps acting for about a day. Even in ORIGIN with medical supervision severe hypoglycaemia was more than three times as common as without glargine.

Povezano

Srodni proizvodi